REG-Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses

ZUG, Switzerland, Aug. 03, 2026 (GLOBE NEWSWIRE) -- * The FDA Division of Neurology provided positive feedback supporting a regulatory pathway for Privosegtor in acute multiple sclerosis (MS) relapses, addressing a significant unmet medical need * The FDA confirmed that existing Privosegtor data can be cross-referenced for a new Investigational New Drug (IND) application in acute MS relapses, planned for submission in the fourth quarter of 2026 * Privosegtor, a novel neuroprotective candidate, continues to advance across core neuro-ophthalmology indications, including optic neuropathies and acute MS relapses, and is transforming Oculis as an emerging leader in neuro-ophthalmology * Oculis will host a virtual R&D Day in the fourth quarter of 2026 to provide further updates on its clinical pipeline Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced positive U.S. Food and Drug Administration (FDA) pre-IND feedback regarding Privosegtor’s clinical development plan in acute multiple sclerosis (MS) relapses.